Garassino, MC, Wakelee, HA, Spicer, J, Liberman, M, Kato, T, Tsuboi, M, Lee, SH, Chen, KN, Dooms, CA, Majem, M, Eigendorff, E, Martinengo, GL, Bylicki, O, Rodriguez-Abreu, D, Chaft, JE, Yang, J, Arunachalam, A, Norquist, JM, Keller, SM, Gao, SG. Health-related quality of life (HRQoL) outcomes from the randomized, double-blind phase 3 KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC). JOURNAL OF CLINICAL ONCOLOGY. 2024; 42(16)DOI:. PMID:. IF:41.900(Q1/1D).

Soler, RS, Vivas, CS, Macias, I, Esteban, AY, Bassam, A, Plazas, JG, Al-Farhat, Y, Cervantes, A, Alfonso, PG, Paez, D, Ruiz-Casado, A, Lopez, C, Arkosy, PF, Furka, A, Rodriguez-Salas, N, Pascual, FJR, Gracian, AC, Hitre, E, Monteagudo, RF, Salvia, MAS. Positive ad hoc results from neoadjuvant Foxy-5 treatment of colon cancer patients in the ongoing phase II NeoFox study. ANNALS OF ONCOLOGY. 2024; 35DOI:10.1016/j.annonc.2024.05.020. PMID:. IF:65.400(Q1/1D).

Tibau, A, Hwang, TJ, Molto, C, Avorn, J, Kesselheim, AS. Clinical Value of Molecular Targets and FDA-Approved Genome-Targeted Cancer Therapies. JAMA Oncology. 2024; 10(5)DOI:10.1001/jamaoncol.2024.0194. PMID:38573645. IF:20.100(Q1/1D).

Salazar, J, Garcia-Planella, E, Fernández-Clotet, A, Esteve, M, Gisbert, JP, Busquets, D, Lucendo, A, Márquez, L, Guardiola, J, Martín-Arranz, MD, Iglesias, E, Monfort, D, Villoria, A, Cañete, F, Bell, O, Ricart, E, Zabana, Y, Chaparro, M, Domènech, E, Gordillo, J. Genetic biomarkers of methotrexate response and safety in Crohn's disease: Data from the Spanish ENEIDA registry. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2024; 90(5)DOI:10.1111/bcp.16017. PMID:38369687. IF:3.000(Q2/4D).

Anguera, G, Mulet, M, Zamora, C, Osuna-Gómez, R, Barba, A, Sullivan, I, Serra-López, J, Cantó, E, Vidal, S, Majem, M. Potential Role of Circulating PD-L1⁺ Leukocytes as a Predictor of Response to Anti-PD-(L)1 Therapy in NSCLC Patients. Biomedicines. 2024; 12(5)DOI:10.3390/biomedicines12050958. PMID:38790920. IF:3.900(Q1/3D).

Alserawan, L, Mulet, M, Anguera, G, Riudavets, M, Zamora, C, Osuna-Gómez, R, Serra-López, J, Joaquín, AB, Sullivan, I, Majem, M, Vidal, S. Kinetics of IFN?-Induced Cytokines and Development of Immune-Related Adverse Events in Patients Receiving PD-(L)1 Inhibitors. Cancers. 2024; 16(9)DOI:10.3390/cancers16091759. PMID:38730712. IF:4.400(Q2/3D).

Riudavets, M, Auclin, E, Mosteiro, M, Dempsey, N, Majem, M, Prelaj, A, López-Castro, R, Bosch-Barrera, J, Pilotto, S, Escalera, E, Tagliamento, M, Mosquera, J, Zalcman, G, Nana, FA, Ponce, S, Albarrán-Artahona, V, Dal Maso, A, Spotti, M, Mielgo, X, Mussat, E, Reyes, R, Benítez, JC, Lupinacci, L, Duchemann, B, De Giglio, A, Blaquier, JB, Audigier-Valette, C, Scheffler, M, Nadal, E, Lopes, G, Signorelli, D, Garcia-Campelo, R, Menis, J, Bluthgen, V, Campayo, M, Recondo, G, Besse, B, Mezquita, L, Planchard, D. Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non-Small-Cell Lung Cancer. Clinical Lung Cancer. 2024; 25(3)DOI:10.1016/j.cllc.2023.11.007. PMID:38105153. IF:3.300(Q2/4D).

Torres-Esquius, S, Llop-Guevara, A, Gutiérrez-Enríquez, S, Romey, M, Teulé, A, Llort, G, Herrero, A, Sánchez-Henarejos, P, Vallmajó, A, González-Santiago, S, Chirivella, I, Cano, JM, Graña, B, Simonetti, S, de Corcuera, ID, Cajal, TRY, Sanz, J, Serrano, S, Otero, A, Churruca, C, Sánchez-Heras, AB, Servitja, S, Guillén-Ponce, C, Brunet, J, Denkert, C, Serra, V, Balmaña, J. Prevalence of Homologous Recombination Deficiency Among Patients With Germline RAD51C/D Breast or Ovarian Cancer. JAMA Network Open. 2024; 7(4)DOI:10.1001/jamanetworkopen.2024.7811. PMID:38648056. IF:9.700(Q1/1D).